Inhibrx Biosciences, Inc. SEC filings INBX
Inhibrx Biosciences, Inc. has 158 filings in SEC EDGAR's recent list, going back to Jan 29, 2024. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 28, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 28, 2026 | — |
| 4 | Insider transaction | Oct 14, 2026 | Oct 14, 2026 |
| 4 | Insider transaction | Sep 28, 2026 | Sep 25, 2026 |
| 4 | Insider transaction | Sep 23, 2026 | Sep 23, 2026 |
| 4/A | Form 4/a | Sep 18, 2026 | Jun 3, 2026 |
| 4/A | Form 4/a | Sep 18, 2026 | Jun 3, 2026 |
| 4/A | Form 4/a | Sep 18, 2026 | Jun 3, 2026 |
| 4/A | Form 4/a | Sep 18, 2026 | Jun 3, 2026 |
| 4 | Insider transaction | Sep 17, 2026 | Sep 16, 2026 |
| 4 | Insider transaction | Sep 15, 2026 | Sep 11, 2026 |
| 144 | Notice of proposed sale | Sep 15, 2026 | — |
| 144 | Notice of proposed sale | Sep 14, 2026 | — |
| 144 | Notice of proposed sale | Sep 11, 2026 | — |
| 4 | Insider transaction | Sep 10, 2026 | Sep 8, 2026 |
| 144 | Notice of proposed sale | Sep 9, 2026 | — |
| 144 | Notice of proposed sale | Sep 8, 2026 | — |
| 4 | Insider transaction | Sep 8, 2026 | Sep 8, 2026 |
| 4 | Insider transaction | Sep 8, 2026 | Sep 8, 2026 |
| 4 | Insider transaction | Sep 8, 2026 | Sep 8, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 3, 2026 | — |
| 4 | Insider transaction | Jun 4, 2026 | Jun 3, 2026 |
| 4 | Insider transaction | Jun 4, 2026 | Jun 3, 2026 |
| 4 | Insider transaction | Jun 4, 2026 | Jun 3, 2026 |
| 4 | Insider transaction | Jun 4, 2026 | Jun 3, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2026 | — |
| 4 | Insider transaction | Apr 27, 2026 | Apr 24, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 11, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jan 21, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 17, 2025 | — |
| 4 | Insider transaction | Oct 9, 2025 | Oct 7, 2025 |
| 4 | Insider transaction | May 29, 2025 | May 28, 2025 |
| 4 | Insider transaction | May 29, 2025 | May 28, 2025 |
| 4 | Insider transaction | May 29, 2025 | May 28, 2025 |
| 4 | Insider transaction | May 29, 2025 | May 28, 2025 |
| 4 | Insider transaction | Apr 2, 2025 | Apr 1, 2025 |
| 4 | Insider transaction | Apr 2, 2025 | Apr 1, 2025 |
| 3 | Initial insider ownership | Apr 2, 2025 | Apr 1, 2025 |
| 4 | Insider transaction | Mar 28, 2025 | Mar 27, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Feb 26, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Feb 26, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 4, 2025 | — |
| 4 | Insider transaction | Dec 17, 2024 | Dec 16, 2024 |
| 4 | Insider transaction | Dec 6, 2024 | Dec 6, 2024 |
| 4 | Insider transaction | Nov 22, 2024 | Nov 19, 2024 |
| SC 13G | Ownership over 5% (passive) | Nov 14, 2024 | — |
| 4 | Insider transaction | Oct 7, 2024 | Oct 3, 2024 |
| 4 | Insider transaction | Sep 16, 2024 | Sep 12, 2024 |
| 4 | Insider transaction | Sep 12, 2024 | Sep 10, 2024 |
| 4 | Insider transaction | Sep 10, 2024 | Sep 6, 2024 |
| 4 | Insider transaction | Sep 3, 2024 | Aug 29, 2024 |
| 4 | Insider transaction | Sep 3, 2024 | Aug 29, 2024 |
| 4 | Insider transaction | Aug 30, 2024 | Aug 28, 2024 |
| 4 | Insider transaction | Aug 26, 2024 | Aug 22, 2024 |
| 4 | Insider transaction | Aug 22, 2024 | Aug 20, 2024 |
| 4 | Insider transaction | Jun 24, 2024 | Jun 24, 2024 |
| 4 | Insider transaction | Jun 7, 2024 | Jun 5, 2024 |
| SC 13G | Ownership over 5% (passive) | Jun 7, 2024 | — |
| 3 | Initial insider ownership | Jun 7, 2024 | May 29, 2024 |
| 4 | Insider transaction | Jun 4, 2024 | May 31, 2024 |
| SC 13D | Ownership over 5% (active) | Jun 3, 2024 | — |
| SC 13D | Ownership over 5% (active) | Jun 3, 2024 | — |
| SC 13G | Ownership over 5% (passive) | May 31, 2024 | — |
| 4 | Insider transaction | May 31, 2024 | May 29, 2024 |
| 4 | Insider transaction | May 30, 2024 | May 30, 2024 |
| 4 | Insider transaction | May 30, 2024 | May 30, 2024 |
| 4 | Insider transaction | May 30, 2024 | May 29, 2024 |
| 4 | Insider transaction | May 30, 2024 | May 29, 2024 |
| 4 | Insider transaction | May 30, 2024 | May 29, 2024 |
| 4 | Insider transaction | May 30, 2024 | May 29, 2024 |
| 4 | Insider transaction | May 30, 2024 | May 30, 2024 |
| 3 | Initial insider ownership | May 24, 2024 | May 24, 2024 |
| 3 | Initial insider ownership | May 24, 2024 | May 24, 2024 |
| 3 | Initial insider ownership | May 24, 2024 | May 24, 2024 |
| 3 | Initial insider ownership | May 24, 2024 | May 24, 2024 |
| 3 | Initial insider ownership | May 24, 2024 | May 24, 2024 |
| 3 | Initial insider ownership | May 24, 2024 | May 24, 2024 |
| 3 | Initial insider ownership | May 24, 2024 | May 24, 2024 |
| 3 | Initial insider ownership | May 24, 2024 | May 24, 2024 |
Showing 83 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- INBX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- La Jolla, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2007919
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.